Merck & vs Pfizer
Merck & and Pfizer are similar in size: $65.01bn and $62.58bn of revenue in their latest fiscal years. Merck & grew faster (1.3% against -1.6%). Merck & kept more of each dollar of sales as profit: a net margin of 28.1% against 12.4%.
| Latest fiscal year | Merck &MRK, 2025 | PfizerPFE, 2025 |
|---|---|---|
| Revenue | $65.01bn | $62.58bn |
| Revenue growth | 1.3% | -1.6% |
| Net income | $18.25bn | $7.77bn |
| Operating margin | — | — |
| Net margin | 28.1% | 12.4% |
| Return on equity | 36.9% | 8.9% |
| Free cash flow | $12.36bn | $9.07bn |
| Cash | $14.56bn | $1.14bn |
| Total debt | $49.34bn | $64.80bn |
| Debt to equity | 93.8% | — |
| Dividend per share | $3.28 | $1.72 |
| Dividend yield | 2.3% | 5.5% |
| Share buybacks | $5.08bn | — |
| Employees | — | 75,000 |
| Market value | $354.85bn | $172.19bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | 79 (Strong) | 78 (Strong) |
| Insider trades, 12 months | 0 buys, 35 sales | 3 buys, 2 sales |